Oragenics, Inc. (NYSE American: OGEN) shares +44.03% to $8860 rocked in the morning session Thursday as it announced that it had entered an agreement with Adjuvance Technologies Inc. for the use of adjuvant TQL1055 in the Terra CoV-2 vaccine against COVID-19. The adjuvants that vaccines are prepared with are added to enhance their immunogenicity. The TQL1055 is a novel, semisynthetic analog of the saponin adjuvant QS-21 with improved stability and manufacturing efficiency.
The preliminary agreement calls for the use of TQL1055 in pre-clinical animal studies supporting the FDA Investigational New Drug application likely to occur mid-2021, with the possibility of entering into a licensing deal for human clinical trials later in the year.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Tests will be conducted on hamsters and mice to assess the vaccine’s immunogenicity, and an IND filing will require a study on rodents to assess toxicology.
Dr. Tyler Martin, Chief Executive Officer of Adjuvance Technologies, noted, “We are delighted to be partnering with Oragenics and believe that our adjuvant, TQL1055, will provide the increased immune response necessary for a successful and widely available coronavirus vaccine.”
